PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.47%
Negative net income growth while AGEN stands at 35.93%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-1.12%
Negative yoy D&A while AGEN is 13.23%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
11.01%
Deferred tax of 11.01% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
20.13%
Less SBC growth vs. AGEN's 88.24%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
171.56%
Less working capital growth vs. AGEN's 629.26%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.25%
Lower AP growth vs. AGEN's 196.86%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
60.10%
Some yoy usage while AGEN is negative at -1789.73%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
20.13%
Some yoy increase while AGEN is negative at -133.35%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
23.86%
Operating cash flow growth at 50-75% of AGEN's 32.34%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-1272.99%
Negative yoy CapEx while AGEN is 13.90%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1272.99%
Both yoy lines negative, with AGEN at -57.29%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-196.64%
Both yoy lines negative, with AGEN at -50.00%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
1193.74%
Stock issuance far above AGEN's 263.38%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.